Evidence map›Paper›PMID 39078588›Full record

ArticleGenes & genomics2024

Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.

Chenhao Xu, Renyi Su, Zhengyang Lu, Yisu Song, Xiaobing Zhang, Wenzhi Shu, Zhe Yang, Runzhou Zhuang, Xiao Xu, Xuyong Wei

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chenhao Xu *Zhejiang University School of Medicine, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Renyi Su *Zhejiang University School of Medicine, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Zhengyang Lu *Zhejiang Chinese Medical University, Hangzhou, 310000, China.
Yisu SongZhejiang University School of Medicine, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Xiaobing ZhangKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, China.
Wenzhi ShuZhejiang University School of Medicine, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Zhe YangShulan (Hangzhou) Hospital, Hangzhou, 310000, China.
Runzhou ZhuangThe First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China.
Xiao XuZhejiang University School of Medicine, Hangzhou, 310058, China. zjxu@zju.edu.cn.
Xuyong WeiZhejiang University School of Medicine, Hangzhou First People's Hospital, Hangzhou, 310006, China. 1315009@zju.edu.cn.ORCID http://orcid.org/0000-0001-8755-5268

Funding

The Fundamental Research Funds for the Central Universities 2022ZFJH003the Hangzhou New Medical Talent Project the Hangzhou New Medical Talent Projectthe Hangzhou West Lake Pearl Project the Hangzhou West Lake Pearl Projectthe Major Research Plan of Key Research and Development Project of Zhejiang Province 2024C03149, 2023C03046The Major Research Plan of the National Natural Science Foundation of China No.92159202the National Key R&D Program of China 2023YFC2306800Zhejiang Provincial Natural Science Foundation of China LQ22H160052
6 · The paper itself

Abstract

backgroundThe combination of Sorafenib and transcatheter arterial chemoembolization (TACE) exhibits limited efficacy in the treatment of certain advanced hepatocellular carcinomas (HCC), and the molecular mechanisms underlying resistance to this combination remain unclear.

objectiveThis study aims to underscore the distinctive contribution of GeoMx DSP technology in elucidating the molecular intricacies of HCC resistance to the Sorafenib and TACE combination.

methodsPatients with advanced HCC during the waiting period before liver transplantation were classified into sensitive and resistant groups based on their response to Sorafenib and TACE combination therapy. Employing GeoMx DSP technology for comprehensive gene expression profiling, we identified pivotal molecular targets linked to resistance against combination therapy.

resultsThe investigation scrutinized intra-tumoral and inter-individual variances, unveiling a spectrum of crucial molecular targets, such as PLG, PLVAP, immunoglobulin genes, ORM1, and NR4A1, among others. Additionally, we explored signaling pathways associated with treatment responsiveness, including the PPAR signaling pathway. Notably, we emphasized the significance of the immune microenvironment characterized by heightened SPP1 expression in HCC resistance to combination therapy. In the resistant group, SPP1

conclusionThe study reveals intra- and inter-individual heterogeneity in HCC that is differentially responsive to the combination of Sorafenib and TACE, highlighting multiple key molecular targets associated with treatment resistance. The immune microenvironment is important, and in particular, SPP1

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticDrug Resistance, NeoplasmLiver NeoplasmsSorafenibAdultAgedAntineoplastic AgentsCombined Modality TherapyFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedTumor MicroenvironmentAntineoplastic AgentsSorafenibCombination therapyHepatocellular carcinoma (HCC)Immune microenvironmentSorafenibSpatial genomicsTranscatheter arterial chemoembolization (TACE)

Identifiers

PMID39078588

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.